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Background. The optimal method of coronary revasculari-
zation in dialysis patients is controversial, as previous small
retrospective studies have reported increased cardiac events
Cardiac disease is the major cause of death in chronicafter percutaneous transluminal coronary angioplasty (PTCA)
dialysis patients, accounting for 44% of overall mortalitycompared with coronary artery bypass (CAB) surgery. The
purpose of this study was to compare the long-term survival [1]. The risk of cardiac death is higher in older patients
of chronic dialysis patients in the United States following and those with diabetic nephropathy, the two groups with
PTCA or CAB surgery. the greatest increase in end-stage renal disease (ESRD)
Methods. Dialysis patients hospitalized from 1978 to 1995
treated with dialysis in the United States. The numberfor first coronary revascularization procedure after initiation
of cardiac interventions in dialysis patients is thus likelyof renal replacement therapy were retrospectively identified
from the United States Renal Data System database. Survival to increase in the United States.
for the endpoints of all-cause death, cardiac death, myocardial The optimal method of coronary revascularization in
infarction, and cardiac death or myocardial infarction was esti- dialysis patients is controversial. All published data on
mated by the life-table method and was compared by the log-
coronary revascularization outcomes in dialysis patientsrank test. The impact of independent predictors on survival
have been limited by retrospective design or small sam-was examined in a Cox regression model with comorbidity
adjustment. ple size. Previous studies have reported unfavorable
Results. The in-hospital mortality was 5.4% for 6887 PTCA outcomes (including increased restenosis) after percuta-
patients and 12.5% for 7419 CAB patients. The two-year event- neous transluminal coronary angioplasty (PTCA) in dial-
free survival (6se) of PTCA patients was 52.9 6 0.7% for all-
ysis patients [2–10] and increased cardiac events withcause death, 72.5 6 0.7% for cardiac death, and 62.0 6 0.7%
PTCA compared with coronary artery bypass (CAB)for cardiac death or myocardial infarction. In CAB patients,
the comparable survivals were 56.9 6 0.6, 75.8 6 0.6, and 71.3 6 surgery [5, 6].
0.6%, respectively (P , 0.02 for PTCA vs. CAB surgery for The purpose of this study was to compare the long-
all endpoints). After comorbidity adjustment, the relative risk term survival of dialysis patients in the United States
of CAB surgery (vs. PTCA) performed 1990 to 1995 for all-
following PTCA or CAB surgery. Using the Unitedcause death was 0.91 (95% CI, 0.86 to 0.97); cardiac death,
States Renal Data System (USRDS) database, we exam-0.85 (95% CI, 0.78 to 0.92); myocardial infarction, 0.37 (95%
CI, 0.32 to 0.43); and cardiac death or myocardial infarction ined the outcome of 14,306 chronic dialysis patients with
0.69 (95% CI, 0.64 to 0.74). coronary revascularization procedures.
Conclusions. In this retrospective study, dialysis patients in
the United States had better survival after CAB surgery com-
pared with PTCA, but our study does not exclude the possibility METHODS
of more unfavorable coronary anatomy in the PTCA patients
All data were derived from the USRDS, which in-at baseline. Our data support the need for prospective trials
cludes data on approximately 92% of all dialysis patients
in the United States [11]. The accuracy of these data hasKey words: chronic kidney failure, coronary artery bypass, percutane-
previously been validated [12].ous transluminal coronary angioplasty, hemodialysis, cardiovascular
disease. The study was a retrospective analysis of dialysis pa-
tients hospitalized for the first coronary revascularizationReceived for publication December 14, 1998
procedure occurring after initiation of renal replacementand in revised form February 11, 1999
Accepted for publication February 26, 1999 therapy from January 1978 to June 1995. Patients were
identified from the USRDS database of 627,983 patients 1999 by the International Society of Nephrology
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Table 1. Patient demographics (N 5 14,306)by International Classification of Diseases codes (ICD-
9-CM) for PTCA (36.01, 36.02, 36.05) or CAB surgery PTCA CAB
(N 5 6,887) (N 5 7,419) P value(36.1). (A total of 123 patients having both procedures
Age ,0.001on the same admission were excluded after a preliminary
,45 760 (11.0%) 747 (10.1%)survival analysis indicated no difference with their inclu-
45–64 3,095 (44.9%) 3,600 (48.5%)
sion in either the PTCA or CAB groups.) Eligible pa- 65–74 2,235 (32.5%) 2,484 (33.5%)
$75 797 (11.6%) 588 (7.9%)tients were receiving renal replacement therapy for 90
Sex ,0.001days or more and were on dialysis for 60 days or more Male 3,845 (55.8%) 4,895 (66.0%)
before revascularization. Patients were excluded for a Female 3,042 (44.2%) 2,524 (34.0%)
Ethnicity ,0.001dialysis duration of less than 60 days before revasculari-
White 5,002 (72.6%) 5,851 (78.9%)zation. Patient demographic data included age, gender, Black 1,545 (22.4%) 1,243 (16.7%)
ethnicity (Hispanic patients not identified in database), Native American 73 (1.1%) 78 (1.0%)
Southeast Asian 167 (2.4%) 146 (2.0%)year of procedure, and primary renal diagnosis. The im-
Other 100 (1.5%) 101 (1.4%)pact of comorbid conditions was examined, because dial- ESRD etiology ,0.001
ysis patient survival is significantly affected by comorbid- Diabetes 2,713 (39.4%) 2,276 (30.7%)
Hypertension 1,812 (26.3%) 2,060 (27.8%)ity [13, 14]. We used a previously developed comorbidity
Other 2,362 (34.3%) 3,083 (41.5%)
profiling methodology based on the ICD-9-CM diagnosis Time of revascularization ,0.001
#1985 0 (0.0%) 769 (10.4%)and procedure codes in the Medicare Part A institutional
1986–1989 1,212 (17.6%) 1,780 (24.0%)inpatient claims [15]. Comorbid conditions were identi-
1990–1995 5,675 (82.4%) 4,870 (65.6%)
fied by ICD-9-CM codes from previous hospitalizations
Abbreviations are: CAB, coronary artery bypass; ESRD, end-stage renal
occurring before the revascularization procedure. Com- disease; PTCA, percutaneous transluminal coronary angioplasty.
orbid conditions include atherosclerotic heart disease
(ASHD) including myocardial infarction, congestive
heart failure (CHF), other cardiac diseases (including
Table 2. In-hospital death by time of revascularizationvalvular heart disease, pacemaker, and arrhythmia), non-
PTCA CABskin malignancies, peripheral vascular disease (PVD),
cerebrovascular ischemia (cerebrovascular accident and All years 371/6887 (5.4%) 930/7419 (12.5%)
#1985 — 72/769 (9.4%)transient ischemic attack), chronic obstructive pulmo-
1986–1989 58/1212 (4.8%) 230/1780 (12.9%)nary disease (COPD), gastrointestinal disease, gallblad- 1990–1995 313/5675 (5.5%) 628/4870 (12.9%)
der disease, and liver disease.
Abbreviations are: CAB, coronary artery bypass; PTCA, percutaneous trans-
luminal coronary angioplasty.In-hospital mortality was estimated. Survival time was
calculated from the time of revascularization to censor or
endpoint. Study endpoints were all-cause death, cardiac
death, acute myocardial infarction (AMI), and the com-
Subject Research Committee of the Hennepin Countybined endpoints of AMI or cardiac death. Censoring
Medical Center Institutional Review Board.occurred if a patient underwent renal transplantation,
had no event at end of study, or was lost to follow-up.
The chi-square test was used to compare differences RESULTS
in demographic characteristics by coronary revasculari- Coronary revascularization procedures were identified
zation procedure. Long-term survival was estimated by in 14,306 dialysis patients (6887 PTCA and 7419 CAB
the life table method [16]. The log-rank test was used surgery). The mean follow-up time (6 sd) after PTCA
to compare the difference in cumulative survival in dif- was 1.59 6 1.51 years (range 0 to 8.73) and 1.88 6 1.92
ferent groups. A Cox proportional hazards model was years (range 0 to 14.97) after CAB surgery. Table 1
used to evaluate the impact of independent predictors summarizes the demographic data. There were small but
(demographics, comorbidity, and ESRD duration prior statistically significant differences in age and ethnicity
to revascularization) on patient survival [17]. The re- for PTCA versus CAB surgery. The CAB group was
ported P values in the Cox model are based on the Wald 66.0% male compared with 55.8% for PTCA. There were
test statistic. All reported P values are two-sided. A proportionally more patients with diabetic renal failure
logistic regression model was also used to assess the having PTCA (39.4%) compared with CAB surgery
impact of independent predictors on patient survival. (30.7%). The time of revascularization was more recent
All statistical analyses were performed under the SAS for PTCA (82.4% in 1990 to 1995) than CAB surgery
system for Windows version 6.12 (SAS Institute, Inc., (65.6% in 1990 to 1995).
Cary, NC, USA). The estimated in-hospital death and event-free sur-
vival are summarized in Tables 2 and 3. The overall in-This study was reviewed and approved by the Human
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Table 3. Event-free survival
All cause Cardiac AMI or cardiac
Years Procedure death death AMI death
1 PTCA 68.960.6% 82.260.5% 87.560.5% 74.260.6%
CAB 70.660.5% 84.260.5% 96.060.3% 81.660.5%
2 PTCA 52.960.7% 72.560.7% 81.260.6% 62.060.7%
CAB 56.960.6% 75.860.6% 91.960.4% 71.360.6%
5 PTCA 23.260.9% 50.061.3% 67.961.4% 39.461.2%
CAB 26.560.8% 51.861.0% 79.361.0% 44.761.0%
Abbreviations are: AMI, acure myocardial infarction; CAB, coronary artery bypass; PTCA, percutaneous transluminal coronary angioplasty. All data are 6
standard error.
hospital death was 5.4% for PTCA and 12.5% for CAB
surgery. For the period of 1990 to 1995, the in-hospital
death was 5.5% for PTCA and 12.9% for CAB surgery.
Despite the greater in-hospital death, the unadjusted
event-free survival was better after CAB surgery for the
endpoints of all-cause and cardiac death, AMI, and the
combined endpoint of AMI or cardiac death. The overall
two-year survival was 56.9% for CAB surgery and 52.9%
after PTCA. The two-year cardiac survival was 75.8%
for CAB surgery and 72.5% after PTCA. At two years,
8.1% of patients with CAB surgery and 18.8% of PTCA
patients had sustained AMI, and 28.7% of patients with
CAB surgery and 38.0% of PTCA patients had either
AMI or cardiac death. Figures 1–4 display the life-table
survival estimates for all-cause death, cardiac death,
AMI, and the combined endpoints of AMI or cardiac
death, respectively. For each endpoint, survival after
CAB surgery versus PTCA was significantly different by
the log-rank test.
The effect of independent predictors of all-cause
death, cardiac death, AMI, and the combined endpoints
of AMI or cardiac death were examined in the Cox
proportional hazards model. Table 4 summarizes inde-
pendent predictors of all-cause death. The most powerful
predictors of death were older age (75 years or more,
Fig. 1. Life table survival estimate: all cause death endpoint. CoronaryRR 5 2.25 with 95% CI, 2.01 to 2.51) and diabetic ESRD
artery bypass (CAB) surgery (black line); percutaneous transluminal
(RR 5 1.37; 95% CI, 1.29 to 1.45). Comorbid conditions coronary angioplasty (PTCA; gray line). Bars are survival 6 se; P 5
0.014.(except ASHD, gallbladder, and liver disease) indepen-
dently contributed to 15 to 26% increased risk of death
in the Cox model. ESRD duration of more than five
years (RR 5 0.92; 95% CI, 0.86 to 0.99) and female
death. Older age and diabetic ESRD were the mostgender were associated with a small survival advantage
powerful predictors of cardiac death. The impact of co-(RR 5 0.94; 95% CI, 0.90 to 0.99). Ethnicity was a more
morbidity on cardiac death was similar to its effect onpowerful predictor of survival, as nonwhite patients had
all-cause death, with PVD independently associated withbetter outcomes. Compared with whites, black patients
15% increased risk and CHF 31% increased risk of car-had a relative risk of death of 0.81 (95% CI, 0.76 to
diac death. Women (RR 5 0.86; 95% CI, 0.81 to 0.92)0.85). Compared with PTCA performed in 1990 to 1995,
and black patients (RR 5 0.80; 95% CI, 0.73 to 0.87)the relative risk of death for CAB surgery performed
had a better cardiac survival. There was a 15% reductionfrom 1990 to 1995 was 0.91 (95% CI, 0.85 to 0.97). PTCA
in cardiac death for CAB surgery (RR 5 0.85; 95% CI,and CAB surgery performed in 1986 to 1989 had 12 and
0.79 to 0.92) versus PTCA performed in 1990 to 1995.15% increased risk of death, respectively, compared with
Both CAB surgery and PTCA performed in 1985 toPTCA performed in 1990 to 1995.
Table 5 summarizes independent predictors of cardiac 1989 had a 20 and 23% increased risk of cardiac death,
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Fig. 2. Life table survival estimate: cardiac death endpoint. Coronary Fig. 3. Life table survival estimate: acute myocardial infarction end-
point. Coronary artery bypass (CAB) surgery (black line); percutaneousartery bypass (CAB) surgery (black line); percutaneous transluminal
coronary angioplasty (PTCA; gray line). Bars are survival 6 se; P 5 transluminal coronary angioplasty (PTCA; gray line). Bars are sur-
vival 6 se; P , 0.0001.0.015.
respectively, compared with PTCA performed 1990 to nary revascularization procedures in 1990 to 1995, was
constructed to analyze further the differential survival1995.
The impact of method of coronary revascularization outcomes for CAB surgery versus PTCA. Despite the
increased peri-procedure mortality associated with sur-on survival was also assessed in a logistic regression
model employing the same variables used in the Cox gery, the log [2 log (survival)] curves of CAB and PTCA
patients (not shown) for all-cause death cross at approxi-model, and similar results were obtained. The odds ratio
for all-cause death was 0.90 (95% CI, 0.83 to 0.98) for mately nine months and at six months for the cardiac
death endpoint. Thus, the short-term survival outcomeCAB surgery versus PTCA performed in 1990 to 1995.
For cardiac death, the odds ratio was 0.85 (95% CI, 0.78 is actually more favorable with PTCA, but at one year
and beyond, the survival outcomes are better with CABto 0.94) for CAB surgery versus PTCA performed in
1990 to 1995. surgery.
Table 6 summarizes independent predictors of AMI.The risk of cardiac death was also analyzed in a Cox
model by diabetic status. In nondiabetics, there was a Age and gender were not predictors of AMI occurrence.
Black patients had a 12% reduction in AMI risk com-10% lower risk of cardiac death after CAB surgery
(RR 5 0.897; 95% CI, 0.806 to 0.998) performed in 1990 pared with white patients. The risk of AMI was 21%
higher in patients with diabetic renal failure. The onlyto 1995 compared with PTCA. In diabetic patients, there
was a 22% lower risk of cardiac death after CAB surgery comorbid conditions associated with increased AMI risk
were prior atherosclerotic heart disease (RR 5 1.33;(RR 5 0.78; 95% CI, 0.68 to 0.89) compared with PTCA
performed in the same period of 1990 to 1995. Figure 5 95% CI, 1.20 to 1.47) and CHF (RR 5 1.14; 95% CI,
1.02 to 1.37). The most powerful predictor of AMI indisplays the estimated cardiac survival of one group
(white, male, age 45 to 64) of diabetic patients after the Cox model was the method of coronary revasculari-
zation. Compared with the reference group of PTCA incoronary revascularization.
A stratified Cox model employing the same variables 1990 to 1995, the risk of AMI was 44% lower for patients
undergoing CAB surgery in 1978 to 1985, 51% lower inin Tables 4 and 5, but restricted to patients having coro-
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Table 4. Cox proportional hazards model for all causes of death
Relative risk ratio
Factor (95% C.I.) P value
Age
45–64 1.28 (1.17, 1.40) ,0.0001
65–74 1.69 (1.54, 1.86) ,0.0001
$75 2.25 (2.01, 2.51) ,0.0001
Gender
Female 0.94 (0.90, 0.99) 0.014
Ethnicity
Native American 0.80 (0.63, 1.03) 0.087
Black 0.81 (0.76, 0.86) ,0.0001
Other 0.84 (0.74, 0.95) 0.006
ESRD etiology
Diabetes 1.37 (1.29, 1.45) ,0.0001
Hypertension 1.15 (1.08, 1.22) ,0.0001
Co-morbidity
ASHD 0.98 (0.93, 1.02) 0.29
CHF 1.26 (1.32, 1.20) ,0.0001
Cardiac (other) 1.20 (1.14, 1.26) ,0.0001
CA 1.17 (1.05, 1.31) 0.006
COPD 1.21 (1.12, 1.31) ,0.0001
CVA/TIA 1.21 (1.12, 1.32) ,0.0001
PVD 1.15 (1.10, 1.21) ,0.0001
GI 1.17 (1.08, 1.25) ,0.0001
Gallbladder 1.07 (0.95, 1.21) 0.24
Liver 1.00 (0.78, 1.28) 1.00
Prior ESRD duration
1–,2 years 1.01 (0.95, 1.07) 0.85
2–5 years 1.03 (0.97, 1.10) 0.28
.5 years 0.92 (0.86, 0.99) 0.029
Time of revascularization
Fig. 4. Life table survival estimate for combined endpoint of acute CAB 78–85 1.19 (1.08, 1.31) 0.0005
myocardial infarction or cardiac death. Coronary artery bypass (CAB) CAB 86–89 1.15 (1.07, 1.23) ,0.0001
surgery (black line); percutaneous transluminal coronary angioplasty CAB 90–95 0.91 (0.86, 0.97) 0.002
(PTCA; gray line). Bars are survival 6 se; P , 0.0001. PTCA 86–89 1.12 (1.03, 1.21) 0.006
Reference group: Age # 44; male; white; other ESRD etiology; no co-morbid-
ity; prior ESRD duration , one year; PTCA 1990–95. Abbreviations are: ASHD,
atherosclerotic heart disease; CA, non-skin malagnancy; CAB, coronary artery
bypass; CHF, congestive heart failure; COPD, chronic obstructive pulmonarypatients with CAB surgery in 1986 to 1989, and 63%
disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; ESRD,
lower for CAB surgery in 1990 to 1995 (all P , 0.0001). end-stage renal disease; GI, gastrointestinal; PTCA, percutaneous transluminal
coronary angioplasty; PVD, peripheral vascular disease.Table 7 summarizes independent predictors of AMI
or cardiac death. The most powerful demographic pre-
dictors were age of 75 or more (RR 5 1.66; 95% CI,
1.44 to 1.91) and diabetic ESRD (RR 5 1.29; 95% CI,
without prior revascularization. At six months after in-1.19 to 1.39). Similar effects of gender, ethnicity, and
tervention, 23% of the CAB group and 60% of the PTCAcomorbid conditions were found for independent risk of
group had recurrent angina, myocardial infarction, orAMI or cardiac death as were noted for cardiac death
cardiac death (P , 0.0001), with a nonsignificant trendalone. There was a marked reduction in the risk of AMI
toward improved survival with surgery (66% two-yearor cardiac death following CAB surgery performed in
survival with CAB surgery, 51% for PTCA). Koyanagi1990 to 1995. Compared with PTCA performed in 1990
et al reported a five-year event-free rate of 70% in 23to 1995, the relative risk of AMI or cardiac death after
dialysis patients with CAB surgery versus 18% in 20CAB surgery performed in 1990 to 1995 was 0.69 (95%
patients with PTCA (P , 0.001) for the combined end-CI, 0.64 to 0.74).
points of cardiac death, coronary revascularization, or
myocardial infarction [5]. A wide variation in reported
DISCUSSION perioperative surgical mortality can be found even in
recent series, ranging from 0 to 5% [5, 6, 18, 19] to aPrevious studies on coronary revascularization out-
surprisingly high 31% in-hospital death [20]. Ivens et alcomes in dialysis patients have generally reported on
reported 4.6% perioperative death in 65 dialysis patientssmall, retrospective series. The largest published series
[18]. The three- and five-year survival rates were 71 andof dialysis patients having coronary revascularization
55%, respectively. In a preliminary communication re-procedures was reported from our institution by Rine-
porting on the largest single institutional experience athart et al [6], retrospectively comparing 60 coronary
artery bypass grafting (CAB) and 24 PTCA patients Emory University (105 PTCA and 84 CAB patients from
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Table 5. Cox proportional hazards model for cardiac death
Relative risk ratio
Factor (95% C.I.) P value
Age
45–64 1.24 (1.10, 1.41) 0.0006
65–74 1.60 (1.40, 1.82) ,0.0001
$75 1.97 (1.69, 2.31) ,0.0001
Gender
Female 0.86 (0.81, 0.92) ,0.0001
Ethnicity
Native American 0.72 (0.49, 1.04) 0.083
Black 0.80 (0.73, 0.87) ,0.0001
Other 0.88 (0.74, 1.05) 0.14
ESRD etiology
Diabetes 1.37 (1.26, 1.49) ,0.0001
Hypertension 1.16 (1.07, 1.26) 0.0004
Co-morbidity
ASHD 0.99 (0.93, 1.06) 0.85
CHF 1.31 (1.22, 1.41) ,0.0001
Cardiac (other) 1.26 (1.17, 1.35) ,0.0001
CA 0.92 (0.76, 1.10) 0.34
COPD 1.07 (0.95, 1.20) 0.28
CVA/TIA 1.17 (1.03, 1.31) 0.012
PVD 1.15 (1.08, 1.23) ,0.0001
GI 1.15 (1.03, 1.27) 0.01
Gallbladder 1.00 (0.84, 1.20) 0.96
Liver 1.14 (0.82, 1.58) 0.43
Prior ESRD duration
1–,2 years 0.95 (0.86, 1.03) 0.22
2–5 years 1.06 (0.98, 1.15) 0.17
.5 years 0.89 (0.80, 0.99) 0.029
Time of revascularization
CAB 78–85 1.29 (1.13, 1.48) 0.0002
CAB 86–89 1.20 (1.09, 1.32) 0.0002
CAB 90–95 0.85 (0.78, 0.92) ,0.0001
Fig. 5. Estimated survival from Cox model for cardiac death endpointPTCA 86–89 1.23 (1.11, 1.38) ,0.0001
of white, male diabetic patients (age 45 to 64 years). Coronary artery
Reference group: Age # 44; male; white; other ESRD etiology; no co-morbid- bypass (CAB) surgery (black line); percutaneous transluminal coronary
ity; prior ESRD duration , one year; PTCA 1990–95. Abbreviations are: ASHD, angioplasty (PTCA; gray line); P , 0.0002.atherosclerotic heart disease; CA, non-skin malignancy; CAB, coronary artery
bypass; CHF, congestive heart failure; COPD, chronic obstructive pulmonary
disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; ESRD,
end-stage renal disease; GI, gastrointestinal; PTCA, percutaneous transluminal
coronary angioplasty; PVD, peripheral vascular disease. The difference in mortality between the two groups was
modest; the unadjusted two-year event-free survival for
the endpoints of all-cause and cardiac death were 56.9 6
0.7% and 75.8 6 0.6% for CAB surgery and 52.9 6 0.7%
1987 to 1995), the in-hospital death was 8.7% for PTCA and 72.5 6 0.7% for PTCA, respectively. When event-
and 14.5% for CAB surgery (abstract; Chang et al, J Am free survival for AMI is analyzed as a single endpoint
Coll Cardiol 29:180A, 1997). Using pooled data available or in combination with cardiac death, there is a greater
in 1993, Ko, Kreiger, and Isom reported a 9% operative improvement in long-term survival after CAB surgery
mortality for CAB surgery in dialysis patients [21]. The versus PTCA. The survival advantage in the surgical
present study provides a more representative picture of group for the all-cause death endpoint occurs approxi-
coronary revascularization outcomes in dialysis patients, mately one year and beyond after revascularization, sug-
as it encompasses the experience of dialysis patients in gesting that conventional PTCA may still be appropriate
the United States, rather than in a single institution. for selected short-term palliative indications.
In our study the long-term survival of dialysis patients A clearer picture of comparative survival after coro-
was more favorable after coronary bypass surgery com- nary revascularization is provided by the Cox model.
pared with coronary angioplasty, despite the higher in- After adjusting for demographics, comorbidity, and time
hospital mortality in the surgical group. Even with a peri- of revascularization (1990 to 1995), we found that there
procedure in-hospital mortality of 5.4% for PTCA and was improved long-term survival of dialysis patients after
12.5% for CAB surgery, the all-cause and cardiac mortal- CAB surgery versus PTCA for all endpoints. The sur-
ity were lower with CAB surgery compared with PTCA. vival improvement after CAB surgery (vs. PTCA) was
Despite the early hazard of increased in-hospital death 9% for all-cause death, 15% for cardiac death, 63% for
for the surgery patients, the one-year all-cause mortality AMI alone, and 31% for the combined endpoints of
AMI and cardiac death in the Cox model.was 29.4% after CAB surgery and 31.1% after PTCA.
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Table 7. Cox proportional hazards model for acute mycardialTable 6. Cox proportional hazards model for acute myocardial
infarction (AMI) infarction (AMI) or cardiac death
Relative risk ratioRelative risk ratio
Factor (95% C.I.) P value Factor (95% C.I.) P value
AgeAge
45–64 1.13 (0.95, 1.35) 0.16 45–64 1.18 (1.06, 1.32) 0.002
65–74 1.40 (1.25, 1.57) ,0.000165–74 1.10 (1.91, 1.33) 0.32
$75 1.17 (0.92, 1.49) 0.20 $75 1.66 (1.44, 1.91) ,0.0001
GenderGender
Female 0.93 (0.84, 1.03) 0.14 Female 0.89 (0.84, 0.94) ,0.0001
EthnicityEthnicity
Native American 0.98 (0.61, 1.59) 0.94 Native American 0.83 (0.61, 1.14) 0.25
Black 0.84 (0.78, 0.91) ,0.0001Black 0.88 (0.771, 0.997) 0.045
Other 0.90 (0.69, 1.16) 0.41 Other 0.88 (0.75, 1.05) 0.11
ESRD etiologyESRD etiology
Diabetes 1.21 (1.06, 1.37) 0.004 Diabetes 1.29 (1.19, 1.39) ,0.0001
Hypertension 1.12 (1.04, 1.21) 0.003Hypertension 1.06 (0.93, 1.20) 0.41
Co-morbidity Co-morbidity
ASHD 1.06 (1.00, 1.13) 0.054ASHD 1.33 (1.20, 1.47) ,0.0001
CHF 1.14 (1.02, 1.28) 0.017 CHF 1.24 (1.16, 1.32) ,0.0001
Cardiac (other) 1.19 (1.12, 1.28) ,0.0001Cardiac (other) 1.08 (0.96, 1.21) 0.19
CA 1.08 (0.83, 1.40) 0.55 CA 0.94 (0.80, 1.10) 0.42
COPD 1.13 (1.02, 1.25) 0.021COPD 1.10 (0.92, 1.31) 0.29
CVA/TIA 1.08 (0.90, 1.31) 0.42 CVA/TIA 1.11 (1.00, 1.24) 0.054
PVD 1.14 (1.07, 1.21) ,0.0001PVD 1.04 (0.94, 1.15) 0.40
GI 1.02 (0.87, 1.21) 0.79 GI 1.11 (1.01, 1.22) 0.025
Gallbladder 0.99 (0.85, 1.16) 0.93Gallbladder 1.03 (0.79, 1.35) 0.81
Liver 1.24 (0.78, 1.96) 0.36 Liver 1.01 (0.74, 1.36) 0.96
Prior ESRD durationPrior ESRD duration
1–,2 years 1.05 (0.92, 1.21) 0.46 1–,2 years 0.99 (0.92, 1.08) 0.89
2–5 years 1.07 (0.99, 1.16) 0.0752–5 years 1.06 (0.93, 1.20) 0.42
.5 years 0.97 (0.82, 1.14) 0.72 .5 years 0.95 (0.87, 1.05) 0.32
Time of revascularizationTime of revascularization
CAB 78–85 0.56 (0.44, 0.69) ,0.0001 CAB 78–85 1.01 (0.90, 1.15) 0.82
CAB 86–89 0.94 (0.86, 1.03) 0.20CAB 86–89 0.49 (0.42, 0.58) ,0.0001
CAB 90–95 0.37 (0.32, 0.43) ,0.0001 CAB 90–95 0.69 (0.64, 0.74) ,0.0001
PTCA 86–89 1.07 (0.98, 1.18) 0.015PTCA 86–89 0.87 (0.74, 1.01) 0.074
Reference group: Age # 44; male; white; other ESRD etiology; no co-morbid-Reference group: Age # 44; male; white; other ESRD etiology; no co-morbid-
ity; prior ESRD duration , one year; PTCA 1990–95. Abbreviations are: ASHD, ity; prior ESRD duration , one year; PTCA 1990–95. Abbreviations are: ASHD,
atherosclerotic heart disease; CA, non-skin malignancy; CAB, coronary arteryatherosclerotic heart disease; CA, non-skin malignancy; CAB, coronary artery
bypass; CHF, congestive heart failure; COPD, chronic obstructive pulmonary bypass; CHF, congestive heart failure; COPD, chronic obstructive pulmonary
disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; ESRD,disease; CVA/TIA, cerebrovascular accident/transient ischemic attack; ESRD,
end-stage renal disease; GI, gastrointestinal; PTCA, percutaneous transluminal end-stage renal disease; GI, gastrointestinal; PTCA, percutaneous transluminal
coronary angioplasty; PVD, peripheral vascular disease.coronary angioplasty; PVD, peripheral vascular disease.
Our findings mirror the Bypass Angioplasty Revascu- and diabetic nephropathy were independent predictors
of all-cause and cardiac death. Our finding of decreasedlarization Investigation study for the importance of dia-
betes in survival after coronary revascularization [22]. mortality of black patients after coronary revasculariza-
tion compared with white patients is consistent with pre-In patients with diabetic renal failure, there was a 22%
decreased cardiac death risk after CAB surgery com- viously published survival data on survival of dialysis
patients in the United States [24, 25]. The 19% reductionpared with PTCA performed in 1990 to 1995. In patients
without diabetic renal failure, there was only a 10% in all-cause death and 20% reduction in cardiac death
risk for black patients compared with white patients isreduction in cardiac death risk after CAB surgery com-
pared with PTCA; this difference was statistically sig- nearly identical to our previously reported survival data
after AMI [26].nificant (P , 0.05). Although diabetes is a identified risk
factor for unfavorable outcomes after coronary revascu- There are several limitations to our study. The USRDS
database provides little clinical data. Important prognos-larization procedures, Barsness et al found no significant
differential effect of diabetes on outcome between pa- tic factors such as left ventricular ejection fraction, the
presence of left main coronary artery disease, and sever-tients receiving PTCA or CAB surgery for multivessel
disease [23]. ity of coronary artery disease are not identified in the
database. Our survival analysis is based on a retrospec-Our study confirms the important impact of comorbid
conditions and demographics on survival in dialysis pa- tive study design, and biased selection for a particular
revascularization procedure could have occurred, whichtients undergoing coronary revascularization. Older age
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transluminal coronary angioplasty for chronic dialysis patients.was not accounted for in our Cox model. Our study
J Invas Cardiol 5:345–350, 1993
cannot exclude the possibility of more unfavorable coro- 3. Gradaus F, Schoebel FC, Ivens K, Jax TW, Heering P, Strauer
nary anatomy in the angioplasty patients at baseline. BE, Leschke M: Restenoserate nach PTCA bei Patienten mit
terminaler Niereninsuffizienz: Eine quantitativ-koronarangiograph-Our data do not address the potential impact of left
ische Untersuchung. Z Kardiol 86:373–379, 1997internal mammary artery grafting on survival after by- 4. Schoebel FC, Gradaus F, Ivens K, Heering P, Jax TW, Grab-
pass surgery. Our study ignores the impact of newer ensee B, Strauer BE, Leschke M: Restenosis after elective coro-
nary balloon angioplasty in patients with end stage renal disease: Amethods of revascularization, particularly stents, which
case-control study using quantitative coronary angiography. Heartmay offer lower rates of restenosis and improved survival 78:337–342, 1997
outcomes compared with conventional coronary angi- 5. Koyanagi T, Nishida H, Kitamura M, Endo M, Koyanagi H,
Kawaguchi M, Magosaki N, Sumiyoshi T, Hosoda S: Comparisonoplasty.
of clinical outcomes of coronary artery bypass grafting and percuta-Percutaneous coronary revascularization is a rapidly neous transluminal coronary angioplasty in renal dialysis patients.
evolving technology (a potential problem frustrating the Ann Thorac Surg 61:1793–1796, 1996
6. Rinehart AL, Herzog CA, Collins AJ, Flack JM, Ma JZ, Op-design of long-term clinical trials), and newer methods
sahl JA: A comparison of coronary angioplasty and coronarymay potentially provide better outcomes than conven- artery bypass grafting outcomes in chronic dialysis patients. Am
tional balloon angioplasty in dialysis patients. The preva- J Kidney Dis 25:281–290, 1995
7. Kahn JK, Rutherford BD, McConahay DR, Johnson WL, Gi-lence of coronary artery restenosis is reportedly higher
orgi LV, Hartzler GO: Short- and long-term outcome of percuta-in dialysis patients after PTCA [2, 3, 7, 8], but the relative neous transluminal coronary angioplasty in chronic dialysis pa-
contribution of aggressive restenosis after PTCA to in- tients. Am Heart J 119:484–489, 1990
8. Ahmed WH, Shubrooks SJ, Gibson M, Baim DS, Bittl JA: Com-creased cardiac morbidity and mortality in dialysis pa-
plications and long-term outcome after percutaneous coronary an-tients is speculative. Newer percutaneous techniques
gioplasty in chronic hemodialysis patients. Am Heart J 128:252–255,
such as directional atherectomy [27–29] rotational ather- 1994
9. Reusser LM, Osborn LA, White HJ, Sexson R, Crawford MH:ectomy [30], and excimer laser [30, 31] have not been
Increased morbidity after coronary angioplasty in patients onshown to offer improved clinical outcomes or lower re-
chronic hemodialysis. Am J Cardiol 73:965–967, 1994
stenosis rates in the non-ESRD population. The most 10. Marso SP, Gimple LW, Philbrick JT, DiMarco JP: Effectiveness
of percutaneous coronary interventions to prevent recurrent coro-promising current techniques for reduction of coronary
nary events in patients on chronic hemodialysis. Am J Cardiolartery restenosis are coronary stents [32–34] and vascular
82:378–380, 1998
radiotherapy [35, 36]. 11. United States Renal Disease System: USRDS 1997 Annual Data
We conclude that dialysis patients in the United States Report. National Institutes of Health, National Institute of Diabe-
tes and Digestive and Kidney Diseases, Bethesda, 1997, pp 21–48have improved survival after CAB surgery compared
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with hemodialysis. Am J Kidney Dis 24:1010–1018, 1994cedures in dialysis patients. Our data support the need 14. Gaylin DS, Held PJ, Port FK: The impact of co-morbid and
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